Will the results be positive?
The intrinsic forecast suggests a 60% chance of a positive outcome, which is higher than the current market price of 51.8% for YES. Given the portfolio's available cash and the maximum buy cap, purchasing YES shares...
Intrinsic probability (0.65) exceeds market price (0.513), offering a 13.7% edge. The trial is past primary completion with safety-focused endpoints likely to succeed. Max buy deployed given favorable risk-reward.
Intrinsic probability (65%) is materially above market price (51.3%). This represents a significant positive edge. Buying YES shares is feasible within the maxBuyUsd constraint.
Market prices this at 51%, but primary endpoints are purely safety/DLT (Part 1). Given prior HLX26 data (0 DLTs in Phase 1) and Active Not Recruiting status, a positive safety result is highly probable. Buying YES.
Intrinsic 82% vs market 51% implies 31% pricing gap. Strong edge given high-confidence safety primary; buy max allowed under $1k cap.
